March 29, 2022 12:22 PM EDT
Pharma
Marketing

Mar­ket­ingRx roundup: No­vo Nordisk Type 1 cy­cling team stars in doc­u­men­tary; GSK, Vi­a­tris, Vi­iV top in­no­va­tion list

Beth Snyder Bulik

Senior Editor

Team No­vo Nordisk’s 17 pro­fes­sion­al cy­clists are all liv­ing with Type 1 di­a­betes and prov­ing with every race what’s pos­si­ble. And now the world is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

A service from the Financial Times